New MedPredict Reports Provide Experts' Strategic Insight on Cardiovascular Markets

Saturday, May 24, 2008 General News J E 4
SCOTTSDALE, Ariz., May 23 MedPredict has released twocompanion reports designed to guide biotech and pharmaceutical decision-makersin cardiovascular therapeutic areas. The reports, one focusing on Non-Interventional Cardiology, and the other focusing on InterventionalCardiology, are based on in-depth interviews with global thought leadersfollowing the 2008 meeting of the American College of Cardiology.

As highlighted in the Non-Interventional Cardiology report, the umbrellatheme for ACC2008 was that having an effect on attributes such as BP or LDLreduction, HDL elevation and even atherosclerotic plaque burden is nice, buthaving an effect on a hard outcome is compelling. The subplot for the meetingwas the litany of trials that didn't quite live up to expectations."Ironically, in the face of this disappointment it was JUPITER, a trial thatwasn't even presented, that created the most positive buzz," according to Dr.Jeffrey Berk, the report's primary author. In the report, the panelists alsodiscuss the numerous combination therapy trials, appropriate endpoints forclinical trial design, and the most compelling compounds in the developmentpipeline.

MedPredict's Interventional report focuses on the role of interventionaland medical therapy in acute coronary syndrome. The discussion covers a broadarray of stents (drug eluting vs. bare metal) and anticoagulants and theirinterplay in the emergency room, the cath lab, the EP lab, the orthopedicsurgical theater and the post-hospital environment. Each panelist shares aperspective on the balance between restenosis, anticoagulant effects, risks ofDVT/PE and bleeding. "In an era of greater restrictions on physiciandetailing, we also asked our panel to outline the differences they see inrepresentatives who market drugs and devices," said Dr. Berk. "The panelprovides specific real-world examples on how hospital-based reps areinfluencing their prescribing behavior."

Some of the companies discussed in these reports include Sanofi-Aventis,GlaxoSmithKline, Bristol Myers Squibb, Merck, AstraZeneca, Bayer, Johnson &Johnson, Boehringer Ingelheim, Pfizer, Astellas, Daiichi Sankyo, Novartis,Solvay, Forest, Takeda, Portola, The Medicines Company, Eli Lilly, CVTherapeutics, Trigen, Schering-Plough, Cordis, Boston Scientific, Medtronic,Abbott, Vascular Solutions, Possis, Gore, Roche, Bard.

About MedPredict

MedPredict ( maintains a proprietary database ofover 1,000 global physician thought leaders, including 40+ specialties in 30+therapeutic categories. MedPredict's reports include thought leader reactionsto recent publications and medical conferences, as well as clinical,regulatory and marketing activity.

SOURCE MedPredict


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
DRAXIS Health Shareholders Approve Acquisition by ...
Lutronic Inc. Announces FDA Clearance of Its Spect...